Back to top
more

Owens & Minor (OMI)

(Real Time Quote from BATS)

$6.37 USD

6.37
751,114

-0.14 (-2.15%)

Updated Aug 6, 2025 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include: Office Depot, Graphic Packaging, Canadian Solar and Owens & Minor

by Zacks Equity Research

Zacks.com featured highlights include: Office Depot, Graphic Packaging, Canadian Solar and Owens & Minor

Zacks Equity Research

Top Ranked Growth Stocks to Buy for August 5th

by Zacks Equity Research

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, August 5th.

Zacks Equity Research

Owens & Minor (OMI) Tops Q2 Earnings Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 5.26% and -4.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

4 Price-to-Book Value Picks to Buy in August

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Zacks Equity Research

Top Ranked Growth Stocks to Buy for August 4th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, August 4th

Zacks Equity Research

Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Owens & Minor (OMI) Stock

by Zacks Equity Research

Owens & Minor (OMI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Owens & Minor, Inc. (OMI) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Owens & Minor, Inc. (OMI).

Zacks Equity Research

Top Ranked Growth Stocks to Buy for July 24th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 24th

Zacks Equity Research

Is Owens & Minor (OMI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Owens & Minor (OMI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout

by Zacks Equity Research

Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.

Zacks Equity Research

Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus

by Zacks Equity Research

Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.

Zacks Equity Research

Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis

by Zacks Equity Research

Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.

Zacks Equity Research

QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff

by Zacks Equity Research

QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.

Zacks Equity Research

Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm

by Zacks Equity Research

Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.

Zacks Equity Research

Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA

by Zacks Equity Research

This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.

Zacks Equity Research

LabCorp Partners With Medable to Expand Technology Ecosystem

by Zacks Equity Research

LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.

Zacks Equity Research

Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

by Zacks Equity Research

Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

Zacks Equity Research

Here's Why You Should Hold on to Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

Zacks Equity Research

Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem

by Zacks Equity Research

NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.

Zacks Equity Research

IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis

by Zacks Equity Research

IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

Zacks Equity Research

Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

by Zacks Equity Research

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

Zacks Equity Research

Medtronic Gets FDA Nod for Guardian CGM's Android Version

by Zacks Equity Research

Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.